ARCHIVES

Phase III Lung and Pancreatic Cancer Trials Are Stopped

This article is from The Cancer Letter archive.

Vol. 33 No. 4 | April 30, 2010

Download PDF Visit The Full Archive

Related Articles

NCCN’s First Physician CEO: Robert Carlson Pledges Broader Research and Policy Agenda

October 5, 2012

Irinotecan And Carboplatin Improve Response In NSCLC

June 24, 2005

The Cancer Letter’s Paul Goldberg Wins Journalism Award

April 10, 2009

More Cost-Effective To Use Cetuximab In Patients With Wild-Type KRAS Gene

August 28, 2009

CIS Celebrates 15th Anniversary, Praised By M. Quayle

December 6, 1991

Radioactive Seeds Tested In Treatment Of NSCLC

September 26, 2008